COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
|
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 50 条
  • [21] Toward more efficient clinical trials for amyotrophic lateral sclerosis
    Cudkowicz, Merit E.
    Katz, Jon
    Moore, Dan H.
    O'neill, Gilmore
    Glass, Jonathan D.
    Mitsumoto, Hiroshi
    Appel, Stanley
    Ravina, Bernard
    Kieburtz, Karl
    Shoulson, Ira
    Kaufmann, Petra
    Khan, Jaffar
    Simpson, Ericka
    Shefner, Jeremy
    Levin, Bruce
    Cwik, Valerie
    Schoenfeld, David
    Aggarwal, Swati
    McDermott, Michael P.
    Miller, Robert G.
    AMYOTROPHIC LATERAL SCLEROSIS, 2010, 11 (03): : 259 - 265
  • [22] Use of vitamins by participants in amyotrophic lateral sclerosis clinical trials
    Prell, Tino
    Grosskreutz, Julian
    PLOS ONE, 2020, 15 (08):
  • [23] Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective
    Wong, Charis
    Stavrou, Maria
    Elliott, Elizabeth
    Gregory, Jenna M.
    Leigh, Nigel
    Pinto, Ashwin A.
    Williams, Timothy L.
    Chataway, Jeremy
    Swingler, Robert
    Parmar, Mahesh K. B.
    Stallard, Nigel
    Weir, Christopher J.
    Parker, Richard A.
    Chaouch, Amina
    Hamdalla, Hisham
    Ealing, John
    Gorrie, George
    Morrison, Ian
    Duncan, Callum
    Connelly, Peter
    Carod-Artal, Francisco Javier
    Davenport, Richard
    Reitboeck, Pablo Garcia
    Radunovic, Aleksandar
    Srinivasan, Venkataramanan
    Preston, Jenny
    Mehta, Arpan R.
    Leighton, Danielle
    Glasmacher, Stella
    Beswick, Emily
    Williamson, Jill
    Stenson, Amy
    Weaver, Christine
    Newton, Judith
    Lyle, Dawn
    Dakin, Rachel
    Macleod, Malcolm
    Pal, Suvankar
    Chandran, Siddharthan
    BRAIN COMMUNICATIONS, 2021, 3 (04)
  • [24] Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis
    Ahangaran, Meysam
    Chio, Adriano
    D'Ovidio, Fabrizio
    Manera, Umberto
    Vasta, Rosario
    Canosa, Antonio
    Moglia, Cristina
    Calvo, Andrea
    Minaei-Bidgoli, Behrouz
    Jahed-Motlagh, Mohammad-Reza
    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2022, 216
  • [25] Clinical Neurogenetics Amyotrophic Lateral Sclerosis
    Harms, Matthew B.
    Baloh, Robert H.
    NEUROLOGIC CLINICS, 2013, 31 (04) : 929 - +
  • [26] Amyotrophic lateral sclerosis: a clinical review
    Masrori, P.
    Van Damme, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (10) : 1918 - 1929
  • [27] A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis
    Lenglet, T.
    Lacomblez, L.
    Abitbol, J. L.
    Ludolph, A.
    Mora, J. S.
    Robberecht, W.
    Shaw, P. J.
    Pruss, R. M.
    Cuvier, V.
    Meininger, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (03) : 529 - 536
  • [28] Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis
    Carlesi, C.
    Pasquali, L.
    Piazza, S.
    Lo Gerfo, A.
    Ienco, E. Caldarazzo
    Alessi, R.
    Fornai, F.
    Siciliano, G.
    ARCHIVES ITALIENNES DE BIOLOGIE, 2011, 149 (01): : 151 - 167
  • [29] Clinical analysis and outcomes of amyotrophic lateral sclerosis with demyelinating polyneuropathy
    Sawa, Nobuhiro
    Kataoka, Hiroshi
    Sugie, Kazuma
    Kawahara, Makoto
    Horikawa, Hirosei
    Kusunoki, Susumu
    Ueno, Satoshi
    AMYOTROPHIC LATERAL SCLEROSIS, 2012, 13 (01): : 125 - 131
  • [30] Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for improvement
    Katyal, Nakul
    Govindarajan, Raghav
    FRONTIERS IN NEUROLOGY, 2017, 8